Skip to content
Clinical Trials – home

MuDr. Zuzana Stejfova

Research site

Czechia Taborska 325/57, Nusle, 140 00 Prague, Czechia

  • Psoriatic arthropathy · Back pain · Rheumatoid arthritis
  • Adult patients

About Specializations

MuDr. Zuzana Stejfova in Prague, Czechia specialises in clinical trials of conditions such as Psoriatic arthropathy, Back pain, Rheumatoid arthritis, and other specialisations. This site conducts important research.

Main research areas of the site

Psoriatic Arthritis

The Revmatologicka ambulance at MuDr. Zuzana Stejfova is conducting research on psoriatic arthritis, an immune system disease. The trial evaluates the efficacy of guselkumab in reducing disease activity.

  • Assess reduction in joint swelling and skin lesions
  • Monitor patient‑reported pain and functional improvement

This work aims to expand treatment options for patients with active disease and supports the site’s commitment to advancing rheumatology care.

Rheumatoid Arthritis

At the same Prague clinic, investigators are comparing baricitinib with standard TNF inhibitors to understand safety concerning Venous Thromboembolism. The focus is on improving therapeutic decision‑making for rheumatoid arthritis.

  • Evaluate incidence of VTE events across treatment groups
  • Assess overall disease control and quality of life

Findings will help refine risk‑benefit assessments for biologic and targeted synthetic therapies in immune‑mediated arthritis.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Taborska 325/57, Nusle140 00 PragueCzechia
Recruiting now
no trials
Conditions studied
3

More sites in PragueCzechia

All trials

Ongoing trials

Clinical trials registered at this site – none is enrolling right now.

Condition
Type of trial
Recruitment status
Quick filters

10 clinical trials

Psoriatic arthropathy

Not recruiting

Study on the Effects and Safety of Guselkumab for Patients with Active Psoriatic Arthritis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Psoriatic arthropathy

Not recruiting

Study of Risankizumab vs. Placebo for Patients with Active Psoriatic Arthritis and Inadequate Response to DMARD Therapy

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Psoriatic arthropathy

Not recruiting

Study on Tildrakizumab for Patients with Active Psoriatic Arthritis Who Have Previously Used Anti-TNF Therapy

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Tildrakizumab
  • Sponsor:Sun Pharmaceutical Industries Limited

Psoriatic arthropathy

Not recruiting

Study on Tildrakizumab for Patients with Active Psoriatic Arthritis Who Have Not Used Anti-TNF Therapy

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Tildrakizumab
  • Sponsor:Iqvia Biotech Limited

Back pain

Not recruiting

Study on the Effects of VER-01, Ibuprofen, and Paracetamol for Patients with Chronic Non-Specific Low Back Pain

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Dronabinol
  • Sponsor:Vertanical GmbH

Psoriatic arthropathy

Not recruiting

Study on Long-Term Safety and Efficacy of Tildrakizumab for Adults with Psoriatic Arthritis

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Tildrakizumab
  • Sponsor:Sun Pharmaceutical Industries Limited

Psoriatic arthropathy

Not recruiting

Study on Izokibep for Improving Symptoms in Patients with Active Psoriatic Arthritis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Izokibep
  • Sponsor:Acelyrin Inc.

Rheumatoid arthritis

Not recruiting

Baricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Eli Lilly & Co.
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Novartis Pharma AG
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.